Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
M C De SantisS Di Cosimo

Abstract

Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients. We analyzed data on consecutive 2600 early-BC cases collected in the registry of Fondazione IRCC Istituto Nazionale dei Tumori, Milano, Italy. Correlation between Ki67 and primary tumor size (T-size) was calculated by Spearman's rank correlation coefficient. Association of ALNM with Ki67 and other tumor characteristics was investigated by logistic regression. Adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated in all cases, and separately analyzed according to age, T-size and BC subtype. Large tumor size strongly associated to ALNM, with an adjusted odds ratio (OR) for each 5-mm increase of 1.32 (95% CI 1.24-1.41), except for triple-negative BC (TNBC) cases. In tumors =10 mm, without lymphovascular invasion, representing the strongest predictor of ALNM (OR 6.09, 95% CI 4.93-7.53), Ki67 resulted particularly informative, with a fourfold increased odds of ALNM for val...Continue Reading

References

Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T CookeP Stanton
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valerie-Jeanne BardouGary M Clark
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José Luiz B BevilacquaKimberly J Van Zee
May 23, 2009·Seminars in Oncology·Carey K AndersArchie Bleyer
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Oct 1, 2011·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN International Ki-67 in Breast Cancer Working Group
Jan 10, 2014·Journal of Clinical Pathology·Nirmala PathmanathanJohn Boyages
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Aug 19, 2015·The Breast : Official Journal of the European Society of Mastology·Carsten DenkertFrederick Klauschen
Mar 20, 2016·British Journal of Anaesthesia·S HeschlM Rigaud
Mar 26, 2016·Breast Cancer Research and Treatment·Lori M van RoozendaalMarjolein L Smidt
Aug 9, 2016·The Breast : Official Journal of the European Society of Mastology·Roopa LakhanpalAngela Rezo
Sep 26, 2016·The Breast : Official Journal of the European Society of Mastology·Fabinshy ThangarajahVerena Kirn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.